Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades
Expedited approvals have improved drug access in GI oncology, but modest benefits highlight the need to balance speed with outcomes that truly matter to patients.
Authors
- Oudai Sahvan (ORCID: https://orcid.org/0000-0001-9837-0891)
- Jeremy Jones (ORCID: https://orcid.org/0000-0001-7793-9540)
- Pedro Luiz Serrano Usón (ORCID: https://orcid.org/0000-0001-6122-1374)
- Mohamad Bassam Sonbol (ORCID: https://orcid.org/0000-0002-6931-242X)
- Fang‐Shu Ou (ORCID: https://orcid.org/0000-0003-1267-8735)
- Tanios Bekaii‐Saab (ORCID: https://orcid.org/0000-0001-7721-1699)
- Fares Jamal (ORCID: https://orcid.org/0009-0007-6286-3855)
Institutions
- Mayo Clinic (US)
- Alliance for Clinical Trials in Oncology (US)
- Jacksonville College (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf381
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00